aluxum With Q2 2024 ending, Wells Fargo this week highlighted the remaining set of biotech catalysts scheduled for the quarter, including trial readouts from companies such as Alnylam Pharmaceuticals ( NASDAQ: ALNY ) and Pliant Therapeutics ( NASDAQ: PLRX ) in the list. Wells Fargo analyst Tiago Fauth and his team predicted an impact on Alnylam ( ALNY ) as the company is set to release topline data from its Phase 3 HELIOS-B trial for its RNAi therapeutic vutrisiran in late June or early July. With HELIOS-B designed to test vutrisiran in ATTR amyloidosis with cardiomyopathy (ATTR-CM), Fauth also cites potential readthrough to ALNY's rival BridgeBio ( BBIO ), whose ATTR-CM therapy acoramidis is currently under FDA priority review.
"We continue to expect a readout that likely meets the primary endpoint but is perceived as undifferentiated, setting up a balanced risk/reward for ALNY and a positive one for BBIO," the analysts with an Equal Weight rating on Alnylam ( ALNY ) wrote. Wells Fargo also cited a bullish set-up for Aerovate Therapeutics ( AVTE ) ahead of a topline readout scheduled in June from the company's IMPAHCT trial for its lead asset AV-101 in pulmonary arterial hypertension (PAH). Given the YTD selloff, the analysts also pointed to positives in Pliant Therapeutics ( PLRX ), which is set to release 24-week data from its INTEGRIS-PSC Phase 2a trial for lead asset bexotegrast against a liver disorder called primary sclerosing cholangitis (PSC).
"We think any value for.